Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 847-854, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deinum, J.
Right arrow Articles by Schalekamp, M. A.D.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deinum, J.
Right arrow Articles by Schalekamp, M. A.D.H.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1999;45:847-854.)
© 1999 American Association for Clinical Chemistry, Inc.

Articles

Improved Immunoradiometric Assay for Plasma Renin

Jaap Deinuma, Frans H.M. Derkx and Maarten A.D.H. Schalekamp

Department of Internal Medicine I, University Hospital Dijkzigt, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
a Author for correspondence. Fax 31 10 4634531; e-mail deinum{at}inw1.azr.nl

Background: Our renin IRMA overestimated renin in plasmas with high prorenin-to-renin ratios. We suspected that the overestimation of renin was caused less by cross-reactivity of the renin-specific antibody with prorenin than by a conformational change of prorenin into an enzymatically active form during the assay.

Methods: Because the inactive form of prorenin converts slowly into an active form at low temperature, we raised the assay temperature from 22 °C to 37 °C, simultaneously shortening the incubation time from 24 to 6 h. The former IRMA was performed in <1 working day with these modifications.

Results: The comeasurement of prorenin as renin was eliminated. Reagents were stable at 37 °C, and the new and old IRMAs were comparable in terms of precision and accuracy. The functional lower limit of the assay (4 mU/L) was below the lower reference limit (9 mU/L). The modified IRMA agreed closely with the activities measured with an enzyme-kinetic assay. Results were not influenced by the plasma concentration of angiotensinogen. At normal angiotensinogen concentrations, the IRMA closely correlated with the classical enzyme-kinetic assay of plasma renin activity.

Conclusion: The modified IRMA, performed at 37 °C, avoids interference by prorenin while retaining the desirable analytical characteristics of the older IRMA and requiring less time.© 1999 American Association for Clinical Chemistry




The following articles in journals at HighWire Press have cited this article:


Home page
 HypertensionHome page
D. J. Campbell
Interpretation of Plasma Renin Concentration in Patients Receiving Aliskiren Therapy
Hypertension, January 1, 2008; 51(1): 15 - 18.
[Full Text] [PDF]

Home page
 HypertensionHome page
A.H. J. Danser and J. Deinum
Renin, Prorenin and the Putative (Pro)renin Receptor
Hypertension, November 1, 2005; 46(5): 1069 - 1076.
[Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
A. J. Danser and J. Deinum
Spotlight on Renin: Renin, Prorenin and the Putative (Pro)renin Receptor
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2005; 6(3): 163 - 165.
[PDF]

Home page
 Clin. Chem.Home page
R. A. de Bruin, A. Bouhuizen, S. Diederich, F. H. Perschel, F. Boomsma, and J. Deinum
Validation of a New Automated Renin Assay
Clin. Chem., November 1, 2004; 50(11): 2111 - 2116.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
O. Olivieri, A. Ciacciarelli, D. Signorelli, F. Pizzolo, P. Guarini, C. Pavan, A. Corgnati, S. Falcone, R. Corrocher, A. Micchi, et al.
Aldosterone to Renin Ratio in a Primary Care Setting: The Bussolengo Study
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4221 - 4226.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Quinkler, B. Meyer, W. Oelkers, and S. Diederich
Renal Inactivation, Mineralocorticoid Generation, and 11{beta}-Hydroxysteroid Dehydrogenase Inhibition Ameliorate the Antimineralocorticoid Effect of Progesterone in Vivo
J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3767 - 3772.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. Andersen, L. Tarnow, F. Cambien, P. Rossing, T. R. Juhl, J. Deinum, and H.-H. Parving
Long-Term Renoprotective Effects of Losartan in Diabetic Nephropathy: Interaction with ACE insertion/deletion genotype?
Diabetes Care, May 1, 2003; 26(5): 1501 - 1506.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
P. Jacobsen, S. Andersen, B. R. Jensen, and H.-H. Parving
Additive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type I Diabetic Patients with Diabetic Nephropathy
J. Am. Soc. Nephrol., April 1, 2003; 14(4): 992 - 999.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. Andersen, P. Rossing, T. R. Juhl, J. Deinum, and H.-H. Parving
Optimal dose of losartan for renoprotection in diabetic nephropathy
Nephrol. Dial. Transplant., August 1, 2002; 17(8): 1413 - 1418.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Piffanelli, A. Morganti, F. Mantero, A. Cianetti, G. C. Zucchelli, G. Giovannini, and D. Pelizzola
Supraregional Interlaboratory Quality-Control Survey for an Immunoradiometric Renin Assay
Clin. Chem., December 1, 2001; 47(12): 2148 - 2150.
[Full Text] [PDF]

Home page
 CirculationHome page
C. Kramers, S. M. Danilov, J. Deinum, I. V. Balyasnikova, N. Scharenborg, M. Looman, F. Boomsma, M. H. de Keijzer, C. van Duijn, S. Martin, et al.
Point Mutation in the Stalk of Angiotensin-Converting Enzyme Causes a Dramatic Increase in Serum Angiotensin-Converting Enzyme But No Cardiovascular Disease
Circulation, September 11, 2001; 104(11): 1236 - 1240.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
T. K. A. WIEREMA, A. J. H. M. HOUBEN, A. A. KROON, D. KOSTER, K. V. D. ZANDER, J. M. A. V. ENGELSHOVEN, and P. W. D. LEEUW
Nitric Oxide Dependence of Renal Blood Flow in Patients with Renal Artery Stenosis
J. Am. Soc. Nephrol., September 1, 2001; 12(9): 1836 - 1843.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J. J. Saris, F. H. M. Derkx, R. J. A. De Bruin, D. H. W. Dekkers, J. M. J. Lamers, P. R. Saxena, M. A. D. H. Schalekamp, and A. H. Jan Danser
High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin
Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1706 - H1715.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. S. Ulmer and A. W. Meikle
Sample Requirements for Plasma Renin Activity and Immunoreactive Renin
Clin. Chem., September 1, 2000; 46(9): 1442 - 1444.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.